

Azee Pharmaceuticals
We plan to rapidly develop and license a new break-through drug for treating chronic pain and, in 3 years, provide a high ROI for investors.
- Stage Product In Development
- Industry Biotechnology
- Location Dublin, CA, USA
- Currency USD
- Founded September 2003
- Employees 1
- Website azeeinc.com
Company Summary
Azee Pharmaceuticals is an early-stage, drug-development company that is developing a new analgesic drug for treatment of chronic pain to address the growing need for more effective therapies. Azee is developing a break-through drug that can acquire significant market share. The business plan focuses on rapidly establishing clinical proof-of-concept, and then in 3 years licensing the drug and giving investors a possible early exit and high ROI.
Team
-
Richard TanakaCEO/Founder
Dr. Tanaka has over 25 years of pharmaceutical experience in both large (Bristol-Myers Squibb) and small companies (Axys Pharmaceuticals, Genesoft Pharmaceuticals). He has worked in multiple therapeutic areas (cardiovascular, inflammation, cancer, infectious disease, chronic pain), and he was also the principal investigator and project leader for a DARPA contract that received $21 million in government funding.
-
Heinz GschwendDirector, Board of Directors
Dr. Gschwend has over 35 years of pharmaceutical experience (former head of central research, Ciba Geigy). Dr. Gschwend also served on the scientific advisory board for several biotech companies.
-
James HudakDirector, Board of Directors
Mr. Hudak has over 20 years of healthcare experience (former CEO of United Behavioral Health). He is currently the CEO of Paradigm Management Services (Walnut Creek, CA).
Advisors
-
Squire, Sanders, and DempseyLawyerUnconfirmedWaterman, Fallahee, Hanson, and AssociatesAccountantUnconfirmed
Previous Investors
-
Mr. James HudakUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.